Skip to content
value.today

Sound Pharmaceuticals Inc.

Total raised
$22 M
4 rounds on record
Latest round
$8 M
May 2018
First round on record
May 2005
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Sound Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2018$8 MNo. 4$2 to $10 million

Sound Pharmaceuticals Inc.: Raise no. 4, May 2018

Investors in this round

5 investors had bought by the notice of Jun 6, 2018: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $10 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, other: Series C-2 Preferred Stock
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John C. Sullivan · Executive Officer
  • Jonathan Kil · Executive Officer, Director
  • David Guyer · Director
  • Glenn Kawasaki · Director
  • James C. Towne · Director
  • Joseph Ashley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The amounts above include the conversion of note principal and interest. Actual Total Offering Amount $10,408,575.34; Actual Total Amount Sold $8,408,575.34.”

Signed by John Sullivan, Chief Financial Officer. Source: SEC Form D, newest notice filed Jun 6, 2018. Read the notice at the SEC.

equitySEC
Aug 2015$4 MNo. 3$2 to $10 million

Sound Pharmaceuticals Inc.: Raise no. 3, Aug 2015

Investors in this round

4 investors had bought by the notice of Sep 16, 2016: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $5 M offered; $1 M still to sell
Smallest investment taken
$300,000
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Washington

People named in the notice

  • Eric Lynch · Executive Officer, Director
  • James Paul Rickey · Executive Officer
  • Jonathan Kil · Executive Officer, Director
  • Glenn Kawasaki · Director
  • Joseph Ashley · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Paul Rickey, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 16, 2016. Read the notice at the SEC.

debt, optionsSEC
Dec 2012$2 MNo. 2Under $2 million

Sound Pharmaceuticals Inc.: Raise no. 2, Dec 2012

Investors in this round

9 investors had bought by the notice of Dec 17, 2012: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Washington

People named in the notice

  • Eric Lynch · Executive Officer, Director
  • Glenn Kawasaki · Executive Officer, Director
  • Joseph Ashley · Director
  • Paul Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Eric Lynch, President. Source: SEC Form D, newest notice filed Dec 17, 2012. Read the notice at the SEC.

equity, optionsSEC
May 2005$8 MNo. 1$2 to $10 million

Sound Pharmaceuticals Inc.: Raise no. 1, May 2005

Investors in this round

21 investors had bought by the notice of Oct 16, 2013: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$8 M of $10 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Washington

People named in the notice

  • Eric Lynch · Executive Officer, Director
  • Jonathan Kil · Executive Officer
  • Glenn Kawasaki · Director
  • Joseph Ashley · Director
  • Paul Thompson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Eric Lynch, President & CEO. Source: SEC Form D, newest notice filed Oct 16, 2013. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Sound Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2018).

    SEC Form D · Jun 2018

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Jun 2018

That is all the official record says: Sound Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Sound Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 21 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Sound Pharmaceuticals Inc.
NameRoleNamed in
John C. SullivanExecutive officerJun 2018
Jonathan KilExecutive officerJun 2018
Eric LynchExecutive officerSep 2016
James Paul RickeyExecutive officerSep 2016
Glenn KawasakiExecutive officerDec 2012
David GuyerDirectorJun 2018
Glenn KawasakiDirectorJun 2018
James C. TowneDirectorJun 2018
Jonathan KilDirectorJun 2018
Joseph AshleyDirectorJun 2018
Eric LynchDirectorSep 2016
Paul ThompsonDirectorOct 2013